Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26526887 | 0.88 | ALDH1A1 (0.35) | ALDH1A1TSHRHRH1KCNH2 | |
| SCHEMBL5013430 | 0.85 | ALDH1A1 (0.33) | ALDH1A1TSHR | |
| SCHEMBL23395171 | 0.85 | ALDH1A1 (0.33) | ALDH1A1TSHRKDM4E | |
| SCHEMBL5013427 | 0.83 | ALDH1A1 (0.32) | ALDH1A1TSHR | |
| SCHEMBL2207385 | 0.78 | — | — | |
| SCHEMBL23565497 | 0.77 | CA2 (0.34) | ALDH1A1TSHRLMNAKDM4E | |
| SCHEMBL16313108 | 0.72 | ALDH1A1 (0.37) | ALDH1A1TSHRHRH1KCNH2 | |
| SCHEMBL2926049 | 0.70 | — | — | |
| SCHEMBL5959974 | 0.70 | ALDH1A1 (0.42) | ALDH1A1TSHRHRH1KCNH2KDM4E | |
| SCHEMBL17001553 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365592-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230339882-A1 | SHP2 INHIBITOR AND COMPOSITION AND APPLICATION THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| EP-3074402-B1 | BICYCLOAMINE-SUBSTITUTED-N-BENZENESULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME (US) | 2019-01-16 | — | — | EP | disclosed |
| US-20160008339-A1 | PSORALEN DERIVATIVES FOR PREVENTING OR TREATING HEART FAILURE OR CARDIAC HYPERTROPHY | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2016-01-14 | — | — | US | disclosed |
| US-8318701-B2 | Phosphonate analogs of HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120107274-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20110288053-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-8022083-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-8012941-B2 | Carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20110184026-A1 | C4-SUBSTITUTED ALPHA-KETO OXAZOLES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-07-28 | — | — | US | disclosed |
| US-20090131372-A1 | PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES | CHEN JAMES M | 2009-05-21 | — | — | US | disclosed |
| US-20090029939-A1 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2009-01-29 | — | — | US | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-20080153783-A1 | Pyrimidyl Phosphonate Antiviral Compounds and Methods of Use | GILEAD SCIENCES, INC. (US) | 2008-06-26 | — | — | US | disclosed |
| US-7300924-B2 | Anti-infective phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-20070190523-A1 | Method and compositions for identifying anti-hiv therapeutic compounds | GILEAD SCIENCES, INC. | 2007-08-16 | — | — | US | disclosed |
| US-7253180-B2 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-20070072809-A1 | Antiviral compounds | GILEAD SCIENCES, INC. | 2007-03-29 | — | — | US | disclosed |
| US-20070027116-A1 | Therapeutic phosphonate derivatives | GILEAD SCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153783-A1 | Pyrimidyl Phosphonate Antiviral Compounds and Methods of Use | TYMP, MTAP, PNP | ALDH1A1 2933/4885TSHR 4483/4885HRH1 2771/4885 |
| US-20160008339-A1 | PSORALEN DERIVATIVES FOR PREVENTING OR TREATING HEART FAILURE OR CARDIAC HYPERTROPHY | PAH, P4HA1, NPR3 | ALDH1A1 1758/4885TSHR 436/4885HRH1 280/4885 |
| US-20070072809-A1 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | ALDH1A1 2962/4885TSHR 4829/4885HRH1 3917/4885 |
| US-20110288053-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | ALDH1A1 4754/4885TSHR 4568/4885HRH1 4351/4885 |
| US-20120107274-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, NUDT1, SLC29A2 | ALDH1A1 2287/4885TSHR 816/4885HRH1 1760/4885 |
| US-20090029939-A1 | Pre-organized tricyclic integrase inhibitor compounds | MUS81, CDKL4, INTS6 | ALDH1A1 1902/4885TSHR 3915/4885HRH1 1928/4885 |
| US-20070027116-A1 | Therapeutic phosphonate derivatives | PPP5C, PPP3CA, PPP4R3A | ALDH1A1 3783/4885TSHR 3549/4885HRH1 4284/4885 |
| US-20230365592-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | ALDH1A1 865/4885TSHR 3622/4885HRH1 465/4885 |
| US-20090131372-A1 | PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES | PHOSPHO1, G6PC1, PC | ALDH1A1 2826/4885TSHR 2537/4885HRH1 3992/4885 |
| US-20230339882-A1 | SHP2 INHIBITOR AND COMPOSITION AND APPLICATION THEREOF | PTPRF, PTPRCAP, PTPRJ | ALDH1A1 4192/4885TSHR 3019/4885HRH1 4434/4885 |
| US-20110184026-A1 | C4-SUBSTITUTED ALPHA-KETO OXAZOLES | ACACA, AKR1C4, HSD17B12 | ALDH1A1 333/4885TSHR 3944/4885HRH1 419/4885 |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | ALDH1A1 3337/4885TSHR 4782/4885HRH1 3845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.